Loading...
OTCM
PAIOF
Market cap142kUSD
Aug 29, Last price  
0.02USD
Name

Paion AG

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.31%
Rev. gr., 5y
157.99%
Revenues
33m
+366.42%
0000000000000002,765,9008,000,00019,655,1047,128,36533,248,000
Net income
-579k
0000-10,511,6500000000000002,222,1430-579,000
CFO
6m
000-14,950,860-13,155,570000000000000906,12605,941,000

Profile

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
URL
https://www.paion.com/
IPO date
Mar 29, 2012
Employees
71
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
33,248
366.42%
Cost of revenue
29,643
Unusual Expense (Income)
NOPBT
3,605
NOPBT Margin
10.84%
Operating Taxes
378
Tax Rate
10.49%
NOPAT
3,227
Net income
(579)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,432
Long-term debt
19,519
Deferred revenue
Other long-term liabilities
26
Net debt
10,322
Cash flow
Cash from operating activities
5,941
CAPEX
(1,586)
Cash from investing activities
(1,586)
Cash from financing activities
(126)
FCF
3,617
Balance
Cash
10,629
Long term investments
Excess cash
8,967
Stockholders' equity
(136,876)
Invested Capital
163,554
ROIC
3.50%
ROCE
13.51%
EV
Common stock shares outstanding
7,134
Price
Market cap
EV
EBITDA
5,313
EV/EBITDA
Interest
2,803
Interest/NOPBT
77.75%